Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genscript Biotech ( (HK:1548) ) just unveiled an announcement.
Genscript Biotech Corporation has announced amendments to its 2019 and 2021 Restricted Share Unit (RSU) Schemes. The changes include the use of treasury shares for settling vested awards, clarifying the structure of awards as restricted share units, and implementing administrative refinements. These amendments are seen as procedural and align with good corporate governance standards, aiming to facilitate the administration and implementation of the schemes, ultimately benefiting the company and its shareholders.
The most recent analyst rating on (HK:1548) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a company incorporated in the Cayman Islands, operating within the biotechnology industry. It focuses on providing innovative products and services, particularly in the field of gene synthesis and biotechnology solutions.
YTD Price Performance: 37.20%
Average Trading Volume: 10,617,308
Technical Sentiment Signal: Sell
Current Market Cap: HK$29.36B
For a thorough assessment of 1548 stock, go to TipRanks’ Stock Analysis page.